|
1.
|
McLaughlin PJ, Keiper CL, Verderame MF, Zagon IS. Targeted overexpression of OGFr in epithelium of transgenic mice suppresses cell proliferation and impairs full-thickness wound closure. Am J Physiol Regul Integr Comp Physiol. 2012 May; 302(9):R1084-90.
|
|
|
|
|
2.
|
Bronson SK, Verderame MF, Keil RL. Interdisciplinary graduate education: a case study. Cell. 2011 Dec 9; 147(6):1207-8.
|
|
|
|
|
3.
|
Manni A, Xu H, Washington S, Aliaga C, Das A, Cooper T, Richie JP, Prokopczyk B, Calcagnotto A, Trushin N, Van den Heuvel JP, Hamilton C, Demers LM, Liao J, Verderame MF, El-Bayoumy K. The effects of Tamoxifen and fish oil on mammary carcinogenesis in polyoma middle T transgenic mice. Horm Cancer. 2011 Aug; 2(4):249-59.
|
|
|
|
|
4.
|
Manni A, Richie JP, Xu H, Washington S, Aliaga C, Cooper TK, Bruggeman R, Das A, Prokopczyk B, Calcagnotto A, Trushin N, Dickinson R, Liao J, Verderame MF, El-Bayoumy K. Effects of fish oil and Tamoxifen on preneoplastic lesion development and biomarkers of oxidative stress in the early stages of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Int J Oncol. 2011 Nov; 39(5):1153-64.
|
|
|
|
|
5.
|
Manni A, Xu H, Washington S, Aliaga C, Cooper T, Richie JP, Bruggeman R, Prokopczyk B, Calcagnotto A, Trushin N, Mauger D, Verderame MF, El-Bayoumy K. The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Cancer Prev Res (Phila). 2010 Mar; 3(3):322-30.
|
|
|
|
|
6.
|
Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med (Maywood). 2009 May; 234(5):532-41.
|
|
|
|
|
7.
|
Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell. 2009 Jan; 20(1):319-27.
|
|
|
|
|
8.
|
Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer. 2008; 7:5.
|
|
|
|
|
9.
|
Xu H, Washington S, Verderame MF, Manni A. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells. Breast Cancer Res Treat. 2008 Nov; 112(2):255-61.
|
|
|
|
|
10.
|
Manni A, Rager T, Kimball SR, Jefferson LS, Washington S, Hu X, Verderame MF. Effects of alpha-difluoromethylornithine on thrombospondin-1 production by human breast cancer cells. Int J Oncol. 2007 Nov; 31(5):1187-91.
|
|
|
|
|
11.
|
Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res. 2007 Nov 1; 67(21):10511-8.
|
|
|
|
|
12.
|
Ongeri EM, Verderame MF, Hammond JM. The TATA binding protein associated factor 4b (TAF4b) mediates FSH stimulation of the IGFBP-3 promoter in cultured porcine ovarian granulosa cells. Mol Cell Endocrinol. 2007 Nov 15; 278(1-2):29-35.
|
|
|
|
|
13.
|
Zagon IS, Verderame MF, Hankins J, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol. 2007 Apr; 30(4):775-83.
|
|
|
|
|
14.
|
McLaughlin PJ, Verderame MF, Hankins JL, Zagon IS. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med. 2007 Mar; 19(3):421-8.
|
|
|
|
|
15.
|
Xu H, Washington S, Verderame MF, Manni A. Activation of protein kinase A (PKA) signaling mitigates the antiproliferative and antiinvasive effects of alpha-difluoromethylornithine in breast cancer cells. Breast Cancer Res Treat. 2008 Jan; 107(1):63-70.
|
|
|
|
|
16.
|
Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A. Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat. 2008 Jan; 107(1):33-40.
|
|
|
|
|
17.
|
Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A. Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat. 2007 Sep; 105(1):29-36.
|
|
|
|
|
18.
|
Hu X, Washington S, Verderame MF, Manni A. Interaction between Polyamines and the Mitogen-Activated Protein Kinase Pathway in the Regulation of Cell Cycle Variables in Breast Cancer Cells. Cancer Res. 2005 Dec 1; 65(23):11026-33.
|
|
|
|
|
19.
|
Zagon IS, Sassani JW, Verderame MF, McLaughlin PJ. Particle-mediated gene transfer of opioid growth factor receptor cDNA regulates cell proliferation of the corneal epithelium. Cornea. 2005 Jul; 24(5):614-9.
|
|
|
|
|
20.
|
Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-Dupree AE, McLaughlin PJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2005 Nov; 56(5):510-20.
|
|
|
|
|
21.
|
Jaglowski JR, Zagon IS, Stack BC, Verderame MF, Leure-duPree AE, Manning JD, McLaughlin PJ. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2005 Jul; 56(1):97-104.
|
|
|
|
|
22.
|
McLaughlin PJ, Jaglowski JR, Verderame MF, Stack BC, Leure-Dupree AE, Zagon IS. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int J Oncol. 2005 Mar; 26(3):809-16.
|
|
|
|
|
23.
|
Ongeri EM, Verderame MF, Hammond JM. Follicle-stimulating hormone induction of ovarian insulin-like growth factor-binding protein-3 transcription requires a TATA box-binding protein and the protein kinase A and phosphatidylinositol-3 kinase pathways. Mol Endocrinol. 2005 Jul; 19(7):1837-48.
|
|
|
|
|
24.
|
Manni A, Washington S, Hu X, Griffith JW, Bruggeman R, Demers LM, Mauger D, Verderame MF. Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. Clin Exp Metastasis. 2005; 22(3):255-63.
|
|
|
|
|
25.
|
Hu X, Washington S, Verderame MF, Demers LM, Mauger D, Manni A. Biological activity of the S-adenosylmethionine decarboxylase inhibitor SAM486A in human breast cancer cells in vitro and in vivo. Int J Oncol. 2004 Dec; 25(6):1831-8.
|
|
|
|
|
26.
|
Smith JP, Stanley WB, Verderame MF, Zagon IS. The functional significance of the cholecystokinin-C (CCK-C) receptor in human pancreatic cancer. Pancreas. 2004 Nov; 29(4):271-7.
|
|
|
|
|
27.
|
Smith JP, Verderame MF, Ballard EN, Zagon IS. Functional significance of gastrin gene expression in human cancer cells. Regul Pept. 2004 Mar 15; 117(3):167-73.
|
|
|
|
|
28.
|
Ongeri EM, Zhu Q, Verderame MF, Hammond JM. Insulin-like growth factor-binding protein-3 in porcine ovarian granulosa cells: gene cloning, promoter mapping, and follicle-stimulating hormone regulation. Endocrinology. 2004 Apr; 145(4):1776-85.
|
|
|
|
|
29.
|
Manni A, Washington S, Mauger D, Hackett DA, Verderame MF. Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells. Clin Exp Metastasis. 2004; 21(5):461-7.
|
|
|
|
|
30.
|
Meehan WJ, Samant RS, Hopper JE, Carrozza MJ, Shevde LA, Workman JL, Eckert KA, Verderame MF, Welch DR. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem. 2004 Jan 9; 279(2):1562-9.
|
|
|
|
|
31.
|
Zagon IS, Verderame MF, McLaughlin PJ. The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides. 2003 Oct; 37(5):290-7.
|
|
|
|
|
32.
|
Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol. 2003 Sep; 86(3-5):477-86.
|
|
|
|
|
33.
|
Zagon IS, Essis FM, Verderame MF, Healy DA, Atnip RG, McLaughlin PJ. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg. 2003 Mar; 37(3):636-43.
|
|
|
|
|
34.
|
Manni A, Washington S, Craig L, Cloud M, Griffith JW, Verderame MF, Texter LJ, Mauger D, Demers LM, Harms JF, Welch DR. Effects of alpha-difluoromethylornithine on local recurrence and pulmonary metastasis from MDA-MB-435 breast cancer xenografts in nude mice. Clin Exp Metastasis. 2003; 20(4):321-5.
|
|
|
|
|
35.
|
Smith JP, Verderame MF, McLaughlin P, Martenis M, Ballard E, Zagon IS. Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. Int J Mol Med. 2002 Dec; 10(6):689-94.
|
|
|
|
|
36.
|
Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. 2002 Feb; 38(3):351-76.
|
|
|
|
|
37.
|
Manni A, Washington S, Griffith JW, Verderame MF, Mauger D, Demers LM, Samant RS, Welch DR. Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis. 2002; 19(2):95-105.
|
|
|
|
|
38.
|
Samant RS, Debies MT, Shevde LA, Verderame MF, Welch DR. Identification and characterization of the murine ortholog (brms1) of breast-cancer metastasis suppressor 1 (BRMS1). Int J Cancer. 2002 Jan 1; 97(1):15-20.
|
|
|
|
|
39.
|
Manni A, Fischer S, Franks M, Washington S, De Arment R, Griffith J, Demers L, Verderame M, Leiby B, Mauger D. S-adenosylmethionine decarboxylase overexpression reduces invasiveness and tumorigenicity in nude mice of MCF-7 breast cancer cells. Int J Oncol. 2001 Aug; 19(2):317-23.
|
|
|
|
|
40.
|
Manni A, Trout D, Verderame MF, Washington S, Mauger D, Demers L. Effect of alpha-difluoromethyl-ornithine on the expression and function of the epidermal growth factor receptor in human breast epithelial cells in culture. Breast Cancer Res Treat. 2001 Jul; 68(2):139-46.
|
|
|
|
|
41.
|
Zagon IS, Verderame MF, Zimmer WE, McLaughlin PJ. Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouse. Brain Res Mol Brain Res. 2000 Dec 8; 84(1-2):106-14.
|
|
|
|
|
42.
|
Zagon IS, Roesener CD, Verderame MF, Ohlsson-Wilhelm BM, Levin RJ, McLaughlin PJ. Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol. 2000 Nov; 17(5):1053-61.
|
|
|
|
|
43.
|
Seraj MJ, Samant RS, Verderame MF, Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 2000 Jun 1; 60(11):2764-9.
|
|
|
|
|
44.
|
Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res. 2000 Feb 21; 856(1-2):75-83.
|
|
|
|
|
45.
|
Samant RS, Seraj MJ, Saunders MM, Sakamaki TS, Shevde LA, Harms JF, Leonard TO, Goldberg SF, Budgeon L, Meehan WJ, Winter CR, Christensen ND, Verderame MF, Donahue HJ, Welch DR. Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis. 2000; 18(8):683-93.
|
|
|
|
|
46.
|
Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, expression and function of a cDNA encoding a receptor for the opioid growth factor, [Met(5)]enkephalin. Brain Res. 1999 Dec 4; 849(1-2):147-54.
|
|
|
|
|
47.
|
Smith JP, Verderame MF, Zagon IS. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett. 1999 Jan 8; 135(1):107-12.
|
|
|
|
|
48.
|
Smith JP, Hamory MW, Verderame MF, Zagon IS. Quantitative analysis of gastrin mRNA and peptide in normal and cancerous human pancreas. Int J Mol Med. 1998 Sep; 2(3):309-15.
|
|
|
|
|
49.
|
Manni A, Wechter R, Verderame MF, Mauger D. Cooperativity between the polyamine pathway and HER-2neu in transformation of human mammary epithelial cells in culture: role of the MAPK pathway. Int J Cancer. 1998 May 18; 76(4):563-70.
|
|
|
|
|
50.
|
Nelle TD, Verderame MF, Leis J, Wills JW. The major site of phosphorylation within the Rous sarcoma virus MA protein is not required for replication. J Virol. 1998 Feb; 72(2):1103-7.
|
|
|
|
|
51.
|
Verderame MF. pp60v-src transformation of rat cells but not chicken cells strongly correlates with low-affinity phosphopeptide binding by the SH2 domain. Mol Biol Cell. 1997 May; 8(5):843-54.
|
|
|
|
|
52.
|
Monschau B, Kremoser C, Ohta K, Tanaka H, Kaneko T, Yamada T, Handwerker C, Hornberger MR, Löschinger J, Pasquale EB, Siever DA, Verderame MF, Müller BK, Bonhoeffer F, Drescher U. Shared and distinct functions of RAGS and ELF-1 in guiding retinal axons. EMBO J. 1997 Mar 17; 16(6):1258-67.
|
|
|
|
|
53.
|
Manni A, Wechter R, Gilmour S, Verderame MF, Mauger D, Demers LM. Ornithine decarboxylase over-expression stimulates mitogen-activated protein kinase and anchorage-independent growth of human breast epithelial cells. Int J Cancer. 1997 Jan 17; 70(2):175-82.
|
|
|
|
|
54.
|
Garnier L, Wills JW, Verderame MF, Sudol M. WW domains and retrovirus budding. Nature. 1996 Jun 27; 381(6585):744-5.
|
|
|
|
|
55.
|
Verderame MF, Nelle TD, Wills JW. The membrane-binding domain of the Rous sarcoma virus Gag protein. J Virol. 1996 Apr; 70(4):2664-8.
|
|
|
|
|
56.
|
Verderame MF, Guan JL, Woods Ignatoski KM. Transformation and pp60v-src autophosphorylation correlate with SHC-GRB2 complex formation in rat and chicken cells expressing host-range and kinase-active, transformation-defective alleles of v-src. Mol Biol Cell. 1995 Aug; 6(8):953-66.
|
|
|
|
|
57.
|
Shao H, Lou L, Pandey A, Verderame MF, Siever DA, Dixit VM. cDNA cloning and characterization of a Cek7 receptor protein-tyrosine kinase ligand that is identical to the ligand (ELF-1) for the Mek-4 and Sek receptor protein-tyrosine kinases. J Biol Chem. 1995 Feb 24; 270(8):3467-70.
|
|
|
|
|
58.
|
Woods KM, Verderame MF. Autophosphorylation is required for high kinase activity and efficient transformation ability of proteins encoded by host range alleles of v-src. J Virol. 1994 Nov; 68(11):7267-74.
|
|
|
|
|
59.
|
Siever DA, Verderame MF. Identification of a complete Cek7 receptor protein tyrosine kinase coding sequence and cDNAs of alternatively spliced transcripts. Gene. 1994 Oct 21; 148(2):219-26.
|
|
|
|
|
60.
|
Verderame MF, Varmus HE. Highly conserved amino acids in the SH2 and catalytic domains of v-src are altered in naturally occurring, transformation-defective alleles. Oncogene. 1994 Jan; 9(1):175-82.
|
|
|
|
|
61.
|
Serra R, Verderame MF, Isom HC. Transforming growth factor beta 1 partially suppresses the transformed phenotype of ras-transformed hepatocytes. Cell Growth Differ. 1992 Oct; 3(10):693-704.
|
|
|
|
|
62.
|
Verderame MF, Kaplan JM, Varmus HE. A mutation in v-src that removes a single conserved residue in the SH-2 domain of pp60v-src restricts transformation in a host-dependent manner. J Virol. 1989 Jan; 63(1):338-48.
|
|
|
|
|
63.
|
Friedman E, Verderame M, Lipkin M, Pollack R. Altered actin cytoskeletal patterns in two premalignant stages in human colon carcinoma development. Cancer Res. 1985 Jul; 45(7):3236-42.
|
|
|
|
|
64.
|
Friedman E, Verderame M, Winawer S, Pollack R. Actin cytoskeletal organization loss in the benign-to-malignant tumor transition in cultured human colonic epithelial cells. Cancer Res. 1984 Jul; 44(7):3040-50.
|
|
|
|
|
65.
|
Pollack R, Lo A, Steinberg B, Smith K, Shure H, Blanck G, Verderame M. SV40 and cellular gene expression in the maintenance of the tumorigenic syndrome. Cold Spring Harb Symp Quant Biol. 1980; 44 Pt 1,:681-8.
|
|
|
|